EXEL vs. HALO, RGEN, NVAX, CRL, NRC, MEDP, PGEN, LUNA, NBIX, and RVMD
Should you be buying Exelixis stock or one of its competitors? The main competitors of Exelixis include Halozyme Therapeutics (HALO), Repligen (RGEN), Novavax (NVAX), Charles River Laboratories International (CRL), National Research (NRC), Medpace (MEDP), Precigen (PGEN), Luna Innovations (LUNA), Neurocrine Biosciences (NBIX), and Revolution Medicines (RVMD).
Halozyme Therapeutics (NASDAQ:HALO) and Exelixis (NASDAQ:EXEL) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, community ranking, analyst recommendations, institutional ownership, dividends, profitability, earnings and risk.
In the previous week, Exelixis had 5 more articles in the media than Halozyme Therapeutics. MarketBeat recorded 14 mentions for Exelixis and 9 mentions for Halozyme Therapeutics. Exelixis' average media sentiment score of 1.28 beat Halozyme Therapeutics' score of 0.62 indicating that Halozyme Therapeutics is being referred to more favorably in the media.
Halozyme Therapeutics has higher earnings, but lower revenue than Exelixis. Halozyme Therapeutics is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.
97.8% of Halozyme Therapeutics shares are owned by institutional investors. Comparatively, 85.3% of Exelixis shares are owned by institutional investors. 2.7% of Halozyme Therapeutics shares are owned by insiders. Comparatively, 2.9% of Exelixis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Halozyme Therapeutics has a net margin of 36.94% compared to Halozyme Therapeutics' net margin of 11.10%. Exelixis' return on equity of 225.71% beat Halozyme Therapeutics' return on equity.
Halozyme Therapeutics has a beta of 1.26, suggesting that its share price is 26% more volatile than the S&P 500. Comparatively, Exelixis has a beta of 0.57, suggesting that its share price is 43% less volatile than the S&P 500.
Halozyme Therapeutics presently has a consensus price target of $53.14, indicating a potential upside of 18.17%. Exelixis has a consensus price target of $26.13, indicating a potential upside of 24.05%. Given Halozyme Therapeutics' higher possible upside, analysts plainly believe Exelixis is more favorable than Halozyme Therapeutics.
Exelixis received 75 more outperform votes than Halozyme Therapeutics when rated by MarketBeat users. However, 69.15% of users gave Halozyme Therapeutics an outperform vote while only 68.12% of users gave Exelixis an outperform vote.
Summary
Halozyme Therapeutics beats Exelixis on 11 of the 18 factors compared between the two stocks.
Get Exelixis News Delivered to You Automatically
Sign up to receive the latest news and ratings for EXEL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EXEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Exelixis Competitors List
Related Companies and Tools
